Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by PEI-PEI LI
Bruton's Tyrosine Kinase Inhibitor Restrains WNT Signaling in Chronic Lymphocytic Leukemia
Molecular Medicine Reports
Oncology
Genetics
Molecular Biology
Biochemistry
Cancer Research
Molecular Medicine
Related publications
Ibrutinib: The First Bruton's Tyrosine Kinase Inhibitor
Prescriber
Pharmacology
Tyrosine Kinase Inhibitor Sequencing in Patients With Chronic Myeloid Leukemia
Oncology and Therapy
Oncology
Managing Chronic Myeloid Leukemia Patients Intolerant to Tyrosine Kinase Inhibitor Therapy
Blood Cancer Journal
Oncology
Hematology
Outcomes With Bruton Tyrosine Kinase Inhibition in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma After Progression on Venetoclax
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Discovering Gene Expression Signatures Responding to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia
BMC Medical Genomics
Genetics
Planned Pregnancy in Female Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy
Oncologist
Cancer Research
Medicine
Oncology
The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Exerts Immunomodulatory Activity Towards Tumor-Infiltrating Macrophages
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
the Specific Bruton Tyrosine Kinase Inhibitor Acalabrutinib (ACP-196) Shows Favorable in Vitro Activity Against Chronic Lymphocytic Leukemia B Cells With CD20 Antibodies
Haematologica
Hematology
Current Event-Free Survival After Sequential Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia
Cancer
Cancer Research
Oncology
